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ABSTRACT 
 
Background: Chronic cognitive deficits are frequent in leucin-rich glioma-inactivated 1 protein 
(LGI1) encephalitis. We examined structural and metabolic brain abnormalities following LGI1 
encephalitis and correlated findings with acute and follow-up clinical outcomes. 
Methods: Nine patients underwent prospective multimodal 3 Tesla MRI 33.1±18 months after 
disease onset, including automated volumetry, diffusion tensor imaging (DTI) and magnetic 
resonance spectroscopy (MRS). Data were compared to 9 age- and sex-matched healthy controls. 
Results: Although extratemporal lesions were not present on MRI in the acute stage, tract-based 
spatial statistics analyses of DTI during follow-up showed widespread changes in the cerebral 
and cerebellar white matter (WM), most prominent in the anterior parts of the corona radiata, 
capsula interna and corpus callosum. MRS revealed lower glutamine/glutamate WM levels 
compared to controls. Higher cerebellar grey matter volume was associated with better function 
at disease onset (measured by the modified Rankin Scale), and higher putaminal volume was 
associated with better cognition by Addenbrooke’s Cognitive Examination test at 23.4±7.6 
months. 
Conclusions: Poor clinical outcome following LGI1 encephalitis is associated with global brain 
atrophy and disintegration of white matter tracts. The pathological changes affect not only 
temporomesial structures but also frontal lobes and the cerebellum. 
 
Key words: anti-LGI1 antibody, limbic encephalitis, MR-spectroscopy, volumetry, diffusion 
tensor imaging, cognition 
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1. INTRODUCTION 
 
Antibodies against the LGI1 protein of the voltage-gated potassium channel (VGKC) complex 
result in subacute limbic encephalitis (LE) [1]. While patients with early immunotherapy may 
have a good prognosis [2,3], cognitive deficit develop in most [4,5]. Structural magnetic 
resonance imaging (MRI) showed extratemporal T2 hyperintensities in the early phase with 
faciobrachial (dys)tonic seizures (FBDS) and reduced volume of the whole brain one year after 
FBDS [6-10]. Glucose metabolism is also abnormal in areas outside of the limbic structures 
[8,11-13]. Although these data point to global structural and metabolic alterations, no study 
examined metabolic changes several years after LGI1 encephalitis. Only a single very recent 
study used follow-up MRI to examine chronic global and regional brain changes and its 
correlation with memory [14]. The correlation between prospectively obtained MRI/clinical 
outcomes and clinical/neuroimaging characteristics in the acute phase is not known either.  
Therefore, here we examined (i) MRI alterations in the acute stage of LGI1 encephalitis; (ii) 
evaluated MRI outcomes 33.1±18 months after disease onset by prospectively planned multi-
modal MRI; and (iii) correlated MRI outcomes with functional outcomes during the early and 
later stages of the disease. 
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2. MATERIAL AND METHODS 
 
2.1 Participants 
Nine patients (4 females, age at onset 59.9±14.5), diagnosed with LGI1 LE participated in this 
study (Table 1). The patients were retrospectively identified in our clinical databases over 53 
months (Februar 2009 to July 2013). LGI1-antibodies were present in the serum, and with one 
exception in the cerebrospinal fluid (CSF) (IIFT Autoimmune Mosaic 1, Euroimmun, Lübeck, 
Germany). Three patients were treated in Hungary and six patients were treated in Denmark. 
Nine Hungarian age- and sex-matched healthy volunteers (mean age: 62.00±13.4 years) were 
included, matching criterion of age was ± 3 years. Clinical information was retrospectively 
obtained from medical reports and from interviews with the individual patient’s neurologist. 
Mini-Mental State Examination (MMSE) and modified Rankin scale (mRS) were regularly 
controlled. We performed correlation analysis with MMSE and mRS (i) at the onset; (ii) when 
the lowest (most severe) values were detected 2.4±1.5 months after onset (nadir); and (iii) 
23.4±7.6 months after the onset as follow-up. Addenbrooke’s Cognitive Examination test (ACE) 
was employed 23.4±7.6 months after onset of LGI1 LE [15]. Mental recovery score was 
calculated as the difference between the lowest MMSE score and the MMSE score at 23.4±7.6 
months, and functional recovery score as the difference between the lowest mRS score and the 
mRS at 23.4±7.6 months. The study procedures were approved in Hungary and Denmark by the 
national ethics committees (082403/2015/OTIG and S-20140018). Written informed consents 
were obtained. 
 
2.2 Magnetic resonance imaging  
The initial MRI examinations were performed as part of the diagnostic procedures within one 
month after first occurence of the symptoms, and included axial- and coronal T2-weighted Turbo 
Spin Echo (TSE), axial- and coronal Fluid-Attenuated Inversion Recovery (FLAIR), sagittal T1-
weighted TSE, three-dimensional T1-weighted Magnetization Prepared Rapid Gradient Echo 
(MPRAGE) and single-shot diffusion weighted spin-echo echo planar imaging.  
A prospective multi-modal MRI investigation was performed 33.1±18 months after the disease 
onset at two neuroimaging sites applying identical scanning protocols. Danish patients were 
scanned using a Siemens Magnetom® Verio™ 3T MR scanner and a 32-channel head coil 
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(Siemens, Erlangen, Germany). Hungarian patients were scanned using a Siemens Magnetom® 
Trio™ and a 12-channel head coil. Both MR scanners were equipped with equivalent gradient 
systems (45mT/m @ 200T/m/s) and identical software versions (syngo® MR-B17). Scanning 
protocol consisted of a three-dimensional T1-weighted 1 mm
3 isotropic MPRAGE sequence, 
axial, oblique axial and oblique coronal two-dimensional T2-weighted TSE sequences, a two-
dimensional FLAIR sequence, a two-dimensional single-shot diffusion weighted spin-echo Echo 
Planar Imaging sequence for Diffusion Tensor Imaging (DTI) and 1D PRESS sequence for single 
voxel 1H spectroscopy (MRS) with one voxel placed in the right centrum semiovale (WM voxel) 
and another in the mid-occipital gray matter (GM voxel). Further details on the applied sequences 
are listed in the Supplementary Materials and Methods.  
 
2.3 Data processing 
2.3.1 Visual evaluation of acute phase and follow-up MRI 
The structural MR images acquired in the subacute stage and at follow-up were compared with 
respect to edema and T2/FLAIR hyperintensity of the hippocampus. Evaluation of hippocampal 
sclerosis (increased T2 signal, reduced volume and/or abnormal morphology) was done on 
coronal plane images at the level of the hippocampus (or axial plane if coronal images were 
absent) [16]. 
 
2.3.2 Volumetric analysis of the T1-weighted MRI data  
The partial volume corrected output volumes of caudate nucleus, putamen, pallidum, brain 
stem, hippocampus, amygdala, accumbens region, corpus callosum, cerebellar gray and white 
matter, as well as total cortical white matter and total segmented brain were calculated from 
automated volumetric analysis and were fed to further analyses [17,18]. Details of volumetric 
analysis method are described in the Supplementary Materials and Methods. 
 
2.3.3 Diffusion tensor imaging and Tract-Based Spatial Statistics (TBSS)  
Voxel-wise statistics were performed on the skeletonized data as described in the “Statistical 
analysis” section. For further analyses, mean skeletal FA and MD values were extracted form 
TBSS analysis pipeline and binary masks were generated for FA and MD from the voxels where 
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FA or MD was significantly different between patients and controls [19-22]. Evaluation details 
are described in Supplementary Materials and Methods. 
 
2.3.4 MR Spectroscopy evaluation  
The CSF corrected concentration of the following metabolites were calculated in all MRS 
voxels [23-25]: total N-acetylaspartate (tNAA), total choline (tCho), total creatine (tCr), myo-
inositole (Ins) and glutamine/glutamate (Glx). Detailed evaluation is described in Supplementary 
Materials and Methods.  
 
2.4 Statistical analyses 
For TBSS analysis, the voxelwise statistics were performed on the skeletonized data using a 
permutation-based non-parametric analysis [26]. Results were considered significant for p<0.05, 
corrected for multiple comparisons using threshold-free cluster enhancement [27], and all 
reported p-values of TBSS analyses are corrected p-values.  
All other statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY). For 
volumetric analysis, between-group comparisons employed multiple linear regression models 
with the volumes of the segmented brain structures as dependent variable and group membership 
(patient/control), age and total intracranial volume as independent variables. The same statistical 
approach was used to test for differences between patients and control subjects regarding brain 
metabolite concentration in GM and WM using the CSF corrected concentrations of metabolites 
as dependent variable, while age and group membership as independent variables. The 
assumptions of multiple linear regression were satisfied, as judged by testing for linearity, 
normality assumptions of the residuals, outliers, independence of errors, homoscedasticity and 
multi-collinearity. Correlation between clinical features measured on a continuous scale (mRS, 
MMSE and ACE) and the volumes of the segmented structures or the CSF corrected 
concentration of brain metabolite were assessed by partial correlations controlling for age and 
total intracranial volume or age respectively. To keep the number of statistical comparisons as 
low as possible for the comparisons with clinical features, only the onset and recovery values 
were used for mRS and MMSE, along with the ACE score measured at 23.4±7.6 months.     
Significance level was set at p<0.05, for multiple comparisons correction Benjamini–Hochberg 
procedure was applied with q=10%. Results of statistical analyses performed with SPSS are 
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reported with uncorrected p-values. However p-values that survive correction for multiple 
comparisons are always clearly marked.    
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3. RESULTS 
 
3.1 Clinical data 
All patients had limbic encephalitis. Although one Danish patient did not have manifest 
epilepsy, there were epileptic discharges in the left temporal lobe beside FBDS and dementia, and 
the patient received antiepileptic treatment (Table 1). Five patients had FBDS. No patient had 
status epilepticus. All patients received antiepileptic treatment. Seven patients received 
immunotherapy in the acute stage, which always included corticosteroids. Five patients received 
additional plasmapheresis, and one patient was treated with intravenous immunoglobulin. 
Immunosuppressive agents were orally administered over 15.2±8.0 months (Table 1). Cognitive 
abilities measured by MMSE at 24 months (median 27; range: 21-30) showed a five points 
improvement compared to nadir at 2.4±1.5 months (median 22; range: 10-28). The functional 
status evaluated by mRS at 23.4±7.6 months (median 2; range: 0-3) displayed a two points 
improvement compared to nadir (median 4; range: 3-5). Five patients showed cognitive decline at 
24 months tested by ACE.  
 
3.2 MRI findings in the acute stage  
Diagnostic MRI scans were taken within one month after disease onset in eight patients 
(Table 2). FLAIR images revealed unilateral (n=5) or bilateral (n=3) hyperintensities in the 
hippocampus in all eight patients. Seven of the eight patients showed unilateral (n=5) or bilateral 
(n=2) hyperintense signal changes in the hippocampus on T2-weighted images, whereas 
enhancing hippocampal lesions were only seen in one out of four patients on contrast-enhanced 
T1-weighted images.  
Seven out of eight patients showed edema in the hippocampus as revealed by FLAIR and 
diffusion-weighted imaging (DWI) (bilateral n=2) (Table 2). Five patients displayed edema in 
the amygdala (bilateral n=2) and the temporal cortex was affected in two cases (unilateral; 
temporopolar and temporomesial).  
None of the patients had extratemporal lesions.  
 
3.3 Comparison of early and follow-up MRI findings 
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MRI data obtained in the subacute stage were compared with those prospectively acquired 
33.1±18 months after disease onset (Table 2). The number of patients identified with edema in 
the hippocampus decreased from 7 to 3 patients: remained unchanged in two, and appeared in 
one patient. Additional edema of the temporal cortex and amygdala on the FLAIR and diffusion-
weighted scans was present on one case. In contrast, hippocampal T2 hyperintensity persisted in 
6 patients (unilateral n=5, bilateral n=1) and FLAIR hyperintensity in seven cases (unilateral n=4, 
bilateral n=3). The extension of the T2/FLAIR hyperintensities decreased in one patient and 
remained constant in the other cases. The frequency of DWI/ADC alteration did not change 
(67%).  
Eight of nine patients developed hippocampal sclerosis (unilateral=5, bilateral=3). All 8 
patients diagnosed in the acute stage with seizures originating from the temporal lobe developed 
hippocampal sclerosis, although the site of epileptic focus and hippocampal sclerosis did not 
correlate. All patients were seizure free at time point of the follow up MRI.   
 
3.4 Volumetric changes 33.1±18 months after disease onset 
The mean volumes (±SD) of the segmented structures, based on the follow-up MRIs, are 
summarized in Supplementary Table 1. The total segmented brain volume was significantly 
lower in patients. Patients had significantly smaller volume in several brain areas (Table 3). 
Next, we correlated the segmented brain structure volumes with the clinical features (mRS, 
MMSE and ACE). For such correlation, we used (i) midline structures with significant group 
differences (brainstem, combined volume of the mid-posterior and central parts of the corpus 
callosum); (ii) the bilateral volumes of those structures where significant difference were shown 
between patients and controls for both sides (cerebral white matter, cerebellar gray matter); (iii) 
and the bilateral volumes of lateral ventricles (a general marker of global atrophy) along with 
putamen and caudate, i.e. areas that have been shown to be highly affected by the disease [7-10]. 
Lower mRS score (better function) at onset was associated with higher cerebellar grey matter 
volume (p=0.002 r=-0.932, passing FDR correction) (Figure 1). Higher ACE test score (better 
cognition) at 23.4±7.6 months was associated with higher putaminal volume (p=0.004 r=0.911, 
passing FDR correction) (Figure 1). We observed additional trends related to mental and 
functional recovery (calculated as the difference between the lowest MMSE score and the MMSE 
score at 23.4±7.6 months, and the difference between the lowest mRS and the mRS at 23.4±7.6 
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months), which did not remain significant after correction for multiple comparisons: higher 
putaminal volume and smaller dilation (volume) of the lateral ventricles was associated with 
better mental recovery ( (p=0.025 r=0.816; and p=0.024, r=-0.819) (Table 4); better functional 
recovery was associated with higher volume of the central parts of the corpus callosum (p=0.04, 
r=0.777) (Table 4). 
 
3.5 Widespread changes in white-matter microstructure 33.1±18 months after disease onset 
Both fractional anisotropy (FA) and mean diffusivity (MD) analysis showed widespread 
reductions in patients (p<0.05) across the cerebellar and cerebral white matter (Supplementary 
Table 2, Supplementary Table 3, Figure 2). The average FA value (mean±SD) calculated from 
the entire FA skeleton was 0.40±0.01 for the healthy control subjects and 0.37±0.02 for the LGI1 
patients. The mean MD value (mean±SD) was 0.83±0.03*10-3mm2*s-1 and 0.86±0.03*10-
3mm2*s-1 respectively. Linear regression analyses controlled for age showed significant group 
differences for both average FA and average MD values (p<0.001 t=-5.445 and p=0.03 t=2.557). 
 
3.6 Metabolic changes in the white and grey matter 33.1±18 months after disease onset 
In the WM voxel, the CSF-corrected glutamine/glutamate concentrations were reduced in the 
patient group (p=0.019, t=-2.627 after correcting for multiple comparisons) (Figure 3). There 
was a trend of reduction in the CSF-corrected choline concentrations (p=0.043, t=-2.210), but this 
was not significant after the FDR correction (Figure 3). A trend of lower glutamine/glutamate 
concentration was found in the GM voxel (p=0.03, t=-2.445, non-significant after correcting for 
multiple comparisons) (Figure 3). Both higher MMSE recovery score and higher ACE test scores 
at 24 months were associated with lower CSF corrected glutamine/glutamate concentrations 
measured in the WM voxel (p=0.013 r=-0.820 and p=0.008 r=-0.847), but neither survived 
correction for multiple comparisons.  
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4. DISCUSSION  
 
In this study, (i) we examined MRI alterations within one month after the onset of LGI1 
encephalitis; (ii) used a prospectively planned multi-modal MRI to evaluate MRI outcomes 
33.1±18 months after disease onset; and (iii) correlated MRI data with clinical outcomes at 
different time points during the course of the disease.   
The most characteristic alterations in the acute LE phase were edema and T2/FLAIR 
hyperintensity of the hippocampus typical of LE [11,28,29]. We did not find extratemporal 
lesions, i.e. basal ganglia hyperintensities in our patients including FBDS cases in contrast to 
earlier studies [9,10,14,30,31]. Nevertheless, we found that higher volume of the putamen was 
associated with better cognition measured by ACE test at 23.4±7.6 months indicating the 
affection of the basal ganglia also in our studies, and that basal ganglia atrophy may affect 
functional outcomes in patients with LGI1 encephalitis. A very recent study also found that a 
longer duration of FBDS correlated with reduction of pallidum volume [14]. FLAIR 
hyperintensity of the hippocampus in the subacute stage was always followed by hippocampus 
atrophy on the same side, while T2 hyperintensity did not show such association. Presence of 
edema despite of clinical remission and seizure free condition may indicate persistent 
inflammation, but earlier epilepsy could also contribute: all 8 patients with manifest epilepsy at 
onset developed hippocampal sclerosis despite of absent seizure activity on follow-up.  
Follow-up volumetry showed a significant volume decrease in the total segmented brain 
volume, white matter, corpus callosum, hippocampus, n. accumbens, brainstem and cerebellum. 
This may indicate that antibodies contribute to global tissue damage, or injury of the limbic 
structures induces secondary changes in other areas. The expression pattern of LGI1 with 
prominent staining in the hippocampus, the neocortex, thalamic nuclei and cerebellum 
corresponds to this observed atrophy, which may suggest a direct damage [32].  
FA analysis also indicated diffuse deterioration of cerebral and cerebellar white matter 
integrity. Despite the lack of extratemporal lesions on conventional MRI during the acute stage, 
the most significant changes were measured in the anterior corona radiata, the anterior half of the 
capsula interna and the anterior 1/3 of the corpus callosum. The affection of frontal areas have 
been described in individual cases with VGKC encephalitis, although some of these patients did 
not have LGI1-antibodies [33,34].  
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We found lower glutamine/glutamate concentrations in the WM compared to controls. A trend 
of lower concentration was seen in the GM voxel, but significance was lost after correcting for 
multiple comparisons. Since decreased glutamine/glutamate ratios were similarly observed in 
patients with depression and mood disorders [35,36], this may suggest the need for increased 
vigilance for affective disturbances in patients following LGI1 encephalitis. Considering 
structural MRI data indicating global atrophy, we expected a significant tNAA difference 
between the LGI1 patients and control subjects. Although the mean tNAA was somewhat lower 
in LGI1 group in both gray- and white matter, the difference was not significant. Since the mean 
age of the patients was around 60 years, it is possible that decrease of tNAA due to aging masks 
loss of tNAA related to the pathological condition.  
We also correlated MRI outcomes with clinical data at onset, when the lowest (most severe) 
values were detected 2.4±1.5 months after onset (nadir), and after 23.4±7.6 months. Better 
functional outcome (mRS) at onset was associated with higher volume of the cerebellar gray 
matter. Such correlation in LGI1 encephalitis has not been described, but visually assessed 
irreversible cerebellar atrophy was associated with poor outcome in a recent study of NMDAR-
encephalitis [37]. Better cognitive capacities measured by the ACE test at 23.4±7.6 months were 
also associated with higher putaminal volumes. The putamen is actively involved in a variety of 
cognitive functions such as episodic memory, cognitive control and category learning [38], and 
its inter-connection with frontal areas and hippocampus play an important role in cognition 
[39,40]. Hyperintensities previously published in VGKC and LGI1 encephalitis/FBDS pointed to 
the affection of these structures, and a very recent study reported correlation between longer 
duration of FBDS and pallidum volume [9,14,28-30]. Although we found decreased hippocampal 
volumes compared to matched controls, hippocampal volumetry did not correlate with ACE and 
mRS outcomes. In a very recent study, larger verbal memory deficits correlated with decreased 
volumes of the left hippocampus and its microstructural integrity [14]. 
In conclusion, our results indicate development of global brain atrophy in patients with LGI1 
LE, despite of early immunotherapy. Besides alterations in the temporal limbic structures, we 
emphasize progressive alterations in the frontal lobe and the cerebellum. These changes may 
contribute to persistent cognitive dysfunction. Metabolic changes detected with MR spectroscopy 
indicate neuroinflammation and abnormal glutamine and glutamate levels. These results argue for 
the need of early, immediate treatment of LGI1 encephalitis. The benefit of patients treated as 
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early as possible with first orwith second line immunotherapy if necessary is proven by several 
studies [41,42].   
Our study is not without limitations. Only 9 patients and 9 control subjects were prospectively 
examined by multimodal MRI in two MR centers, and this may reduce the reliability of the 
applied statistical methods. The number of subjects per variable required for linear regression 
analyses is always subject of intensive debate, rules of thumb are usually between 5-10 subjects 
per variable. Although a recent study showed that adjusted R can be considered reliable at as low 
as 2 subjects per variable in certain cases [43], we tried to keep the numbers as low as possible (2 
variables per 9 subjects or 3 variables per 18 subjects) for linear regression analyses. Since MRI 
in the acute stage of LE was acquired in different institutes using different protocols, the analyses 
of those sequences were limited. As the result of these limitations, further studies are required 
with larger cohorts to confirm our results and conclusions.  
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6. SUPPLEMENTARY MATERIALS AND METHODS 
1. Sequence parameters: 
1.1 T1-weighted MPRAGE sequence with an isotropic resolution of 1 mm to obtain 
anatomical images for MR-based volumetry and registration purposes 
(TR/TI/TE=2530/1100/3.37ms; Flip angle=7°; receiver bandwidth=200Hz/pixel; 176 
contiguous sagittal slices; matrix size=256x256).  
1.2 Two-dimensional T2-weighted turbo spin-echo (TSE) sequences: axial (TR/TE = 
6000/78ms; Flip angle = 120°; receiver bandwidth = 220 Hz/pixel; 43 slices; 0.4mm gap, 
resolution = 0.7 x 0.7 x 4 mm3); oblique axial (TR/TE = 3000/96ms; Flip angle = 120°; 
receiver bandwidth = 220 Hz/pixel; 17 slices; 1.2mm gap, resolution = 0.8 x 0.8 x 4 
mm3); oblique coronal (TR/TE = 3000/96ms; Flip angle = 120°; receiver bandwidth = 220 
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Hz/pixel; 17 slices; 1.2mm gap, resolution = 0.7 x 0.7 x 4 mm3). Oblique slices were 
perpendicular and parallel to the long axis of the hippocampus. 
1.3 FLAIR sequence (TR/TE/TI=5000/95/1800ms; Flip angle=130°; receiver 
bandwidth=287Hz/pixel; 34 slices; 1.2mm gap, resolution=0.9x0.9x4mm3) with oblique 
coronal slice orientation 
1.4 MRS was performed using 1D PRESS sequence (TR/TE=2000/30ms; Flip angle=90°; 
chess water suppression; vector size=1024; delta frequency=-2.7ppm; 
bandwidth=1200Hz; averages=80). Voxel dimensions of white matter (WM) acquisitions 
were 15x15x15mm3, while gray matter (GM) voxels measured 20x15x20mm3. After 
automatic iterative shimming, manual shimming was performed to reduce the FWHM of 
the unsuppressed water signal as much as possible (inclusion criteria were <25Hz for GM 
and <20Hz for WM voxel). A fast reference water signal measurement was performed 
after each voxel with identical sequence properties and shim, except for no water 
suppression applied. 
1.5  DTI images were acquired using a two-dimensional single-shot diffusion weighted spin-
echo Echo Planar Imaging sequence (TR/TE=10100/91ms; 70 axial slices; slice 
thickness=2mm; no gap; FOV=208x256mm2; matrix size=128x128; 
bandwidth=1562Hz/pixel; EPI factor=104). Diffusion gradients were applied in 30 
directions with a b-value of 900 s/mm2 and a single volume was collected with no 
diffusion gradients applied. 
 
2. Volumetric analysis of the T1-weigted MR data: 
MPRAGE images, acquired according to the Freesurfer’s Morphometry Protocols 
Guideline, were fed into volumetric segmentation performed with FreeSurfer v5.3. Details 
of the procedures are described in previous publications [17,18]. Each dataset was 
checked within the processing stream to verify the Talairach transform, the accuracy of 
the skull strip, white matter- and pial surface segmentation, as described in the 
Recommended Reconstruction Workflow. 
 
3. Diffusion tensor imaging and Tract-Based Spatial Statistics (TBSS) evaluation: 
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Diffusion-weighted images were corrected for eddy current distortion and head motion 
using affine registration to a reference volume (B0). After brain extraction of the diffusion 
data using BET [19], FMRIB’s diffusion toolbox  was used to generate voxel-wise images 
of fractional anisotropy (FA) and mean diffusivity (MD) by fitting a diffusion tensor 
model to the data at each voxel of the brain [20]. Voxel-wise statistical analyses of FA 
and MD data were performed using TBSS v1.2 part of FMRIB’s Software Library (FSL) 
[21]. First, all subjects’ FA data were nonlinearly aligned to FMRIB58_FA standard 
space image using FNIRT [22]. Next, the mean FA image was thinned to generate a mean 
FA skeleton, which represents only the center of the white matter tracts common to all 
examined subjects. This mean skeleton was thresholded at FA>0.2. 
 
4. MR spectroscopy evaluation: 
Tissue type segmentation (GM, WM and CSF) of T1-weighted MPRAGE was performed 
using the FAST software implemented in FSL [23]. The binary masks of the MRS voxels 
were constructed in the native coordinate space of the MPRAGE image using Gannet 
software suite [24]. Average CSF content of the spectroscopy voxel was then calculated 
using the CSF image resulting from FAST and the binary mask of the voxel using fslstats. 
Spectroscopy data was evaluated using Tarquin (v4.3.6) with the following parameters: 
TE1=10.8ms; Dynamic corr. ref. signals: 
1H, NAA, Cr, Cho, Lip; Water cutoff=45 Hz; 
Reference signals: 1H, NAA, Cr, Cho, Lip; Auto phase; Auto reference; Eddy Current 
Correction; Internal basis set=1H Brain + Glth; Water concentration=35880mM for WM 
and 43300mM for GM voxels; water attenuation=0.7; λ=0.2; Initial μ=0.001 [24]. As 
normalized fractions within the MRS voxel can be described as fWM+fGM+fCSF=1, the CSF 
corrected metabolite concentration was calculated as C = C0 x 1/(1-fCSF), where C0 is the 
uncorrected metabolite concentration, and fCSF is the average CSF fraction within the 
MRS voxel. 
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LEGENDS 
 
Figure 1 Correlation of cerebellar grey matter and putaminal volume with functional 
outcomes 
Plots A and B were created using demeaned data, where 0 represents the mean value on both 
axes. A. Partial regression plot demonstrating the significant negative relationship between total 
cerebellar grey matter volume and mRS test score at onset after the effects of intracranial volume  
and age was removed. B. Partial regression plots demonstrating the significant positive 
relationships between putaminal volume and ACE test score at 24 months after the effects of 
intracranial volume and age was removed.  
(R2)=linear correlation coefficient, ACE=Addenbrook’s Cognitive Examination, mRS=modified 
Rankin scale 
 
Figure 2 Tract-based spatial statistics analysis of the white matter in patients with LGI1 
limbic encephalitis  
Red/yellow: significant differences (corrected p<0.05) in fractional anisotropy (FA) between 
patients (n=9) and controls (n=9). Blue/light blue: significant differences (corrected p<0.05) in 
mean diffusivity (MD) between patients and controls. Overlapping regions are marked green.  
 
Figure 3 Single-voxel MR spectroscopy in patients with LGI1 limbic encephalitis  
Mid-occipital white (A) and gray matter (B) spectroscopy. Horizontal line: median; +: mean; 
box: interquartile range (25–75%). The difference (p=0.027) in GM has not survived FDR 
correction. tNAA: total N-acetylaspartate; tCho: total choline; tCr: total creatine; Ins: myo-
inositole; Glx: glutamine/glutamate 
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Table 1 Clinical characteristics of the patients with LGI1 limbic encephalitis 
Characteristics Number of patients,  
mean and median values 
Demographics 
Number of patients 
 
9 
Age at onset (mean±SD years) 59.9±14.5  
Sex (male/female) 5/4 
Symptoms (number of patients) 
Faciobrachial dystonic seizures  
Epilepsy 
Temporal lobe epilepsy 
Epileptiform discharges on EEG 
Status epilepticus 
Memory impairment  
Mini-Mental State Examination score at onset (median) 
Mini-Mental State Examination score at nadir (median) 
Mini-Mental State Examination score at 24 months control (median) 
Addenbrooke test score <83 at 24 months control 
Functional ability  
Modified Rankin scale at onset (median) 
Modified Rankin scale at nadirb (median)  
Modified Rankin scale at 24 months (median) 
 
5 
8a 
8a 
7 
0 
 
25 (range: 21-30) 
22 (range: 10-28) 
27 (range: 21-30) 
5 
 
3 (range: 1-4) 
4 (range: 3-5) 
2 (range: 0-3) 
Laboratory abnormalities (serum) 
Serum sodium level <136 mmol/L 
LGI1 antibody 
Other autoimmune antibodies  
 
8 
9 
0 
Therapy  
Start of immunotherapy (months from onset, mean±SD) 
Duration of per os immunotherapy (months, mean±SD) 
Administration of immunotherapy (number of patients) 
 
1.8±1.4 
15.2±8.0 
7 
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Steroids 
Plasma exchange 
Intravenous immunoglobulin 
Other immunosuppressive agents (cyclophosphamide, azathioprine) 
Antiepileptic drugs 
7 
5 
1 
4 
9 
Tumor 0 
aAlthough one Danish patient did not have manifest epilepsy, there were epileptic discharges in 
the left temporal lobe beside FBDS and dementia, and the patient received antiepileptic 
treatment.  
b2.4±1.5 months; reference ranges of laboratory results are given in parenthesis. SD: standard 
deviation; LGI1: Leucin-rich glioma-inactivated 1 protein; EEG: electroencephalography; CSF: 
cerebrospinal fluid 
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Table 2 Characteristics of acute and follow-up conventional MRI sequences by visual 
evaluation in patients with LGI1 limbic encephalitis  
 MRI acute MRI follow-up 
Time from onset of the disease 
(months) (mean±SD) 
≤1 month 
 
33.11±17.97 
 
Edema 
hippocampus 7/8 (88%) 3/9 (33%) 
amygdala  5/8 (63%) 1/9 (11%) 
temporal cortex  2/8 (26%) 1/9 (11%) 
extratemporal 0/8 (0%) 0/9 (0%) 
Hippocampus 
T2 hyperintensity  7/8 (88%) 6/9 (67%) 
FLAIR hyperintensity 8/8 (100%) 7/9 (78%) 
T1 contrast enhancement  1/4 (25%) NA 
DWI/ADC signal changes  4/6 (67%) 6/9 (67%) 
Data are shown as number of patients/available data (percentage) 
FLAIR: fluid-attenuated inversion recovery; DWI: diffusion-weighted imaging; ADC: apparent 
diffusion coefficient; NA: not applicable 
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Table 3 Significant differences in regional brain volumes on follow-up MRI between 
control subjects and patients with LGI1 limbic encephalitis  
Segmented structure      p value       t value 
Left Lateral Ventricle 0.115  1.681 
Left Cerebellum White Matter 0.060 -2.047 
Left Cerebellum Cortex 0.031 -2.391 
Left Thalamus Proper 0.462 -0.756 
Left Caudate 0.652 -0.460 
Left Putamen 0.582  0.563 
Left Pallidum 0.269 -1.151 
Brain Stem <001 -4.524 
Left Hippocampus 0.421 -0.828 
Left Amygdala 0.161  1.480 
Left Accumbens area 0.021 -2.589 
Right Lateral Ventricle 0.006  3.210 
Right Cerebellum White Matter 0.035 -2.330 
Right Cerebellum Cortex 0.017 -2.703 
Right Thalamus Proper 0.049 -2.155 
Right Caudate 0.487 -0.714 
Right Putamen 0.923  0.097 
Right Pallidum 0.481 -0.724 
Right Hippocampus 0.012 -2.869 
Right Amygdala 0.189 -1.380 
Right Accumbens area 0.176 -1.424 
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Corpus Callosum Posterior 0.761 -0.310 
Corpus Callosum Mid Posterior 0.020 -2.635 
Corpus Callosum Central    0.021 -2.611 
Corpus Callosum Mid Anterior 0.153 -1.510 
Corpus Callosum Anterior 0.328 -1.013 
Segmented Brain volume  0.023 -2.553 
Cortical volume, left hemisphere  0.298  1.081 
Cortical volume, right hemisphere  0.869  0.167 
White Matter volume, left hemisphere 0.015 -2.769 
White Matter volume, right hemisphere 0.009 -3.048 
 
Positive t value means larger structure volume in patients. Corrected for age and total 
intracranial volume. P values in bold survive Benjamini–Hochberg procedure for multiple 
comparison correction with q = 10%.  
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Table 4 Significant correlations between clinical features and the volumes of segmented 
structures in patients with LGI1 limbic encephalitis  
  Cerebral 
WM 
Total 
cerebellar 
GM 
CC MID 
+ Central 
Bilateral 
Ventricle 
Brain-
stem 
Putamen Caudate 
mRS 
onset 
Correlation -0.110 -0.932 -0.304 -0.235 -0.619 0.438 0.208 
Significance 
(2-tailed) 
0.814  0.002 0.507 0.612 0.138 0.326 0.655 
mRS 
recoverya 
Correlation  0.729  0.550 0.777 -0.376 0.105 0.239 0.385 
Significance 
(2-tailed) 
 0.063  0.201 0.040 0.406 0.823 0.606 0.394 
MMSE 
onset 
Correlation  0.134  -0.446 -0.063 -0.739 -0.645 -0.057 -0.203 
Significance 
(2-tailed) 
 0.775   0.315 0.893 0.058 0.118 0.904 0.663 
MMSE 
recoveryb 
Correlation  0.248  -0.402 0.064 -0.819 -0.597 0.816 0.014 
Significance 
(2-tailed) 
 0.591   0.371 0.892 0.024 0.157 0.025 0.976 
ACE at 
24 months 
Correlation  0.134  -0.446 -0.063 -0.739 -0.645 0.911 0.168 
Significance 
(2-tailed) 
 0.775   0.315 0.893 0.058 0.118 0.004 0.719 
 
Controlled for age and total intracranial volume. mRS: modified Rankin scale, ACE: 
Addenbrooke’s Cognitive Examination, MMSE: Mini-Mental State Examination. aDifference 
between the lowest mRS score and the mRS score at 23.4±7.6 months, bDifference between the 
lowest MMSE score and the MMSE score at 23.4±7.6 months. WM: white matter, GM: gray 
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matter, CC: corpus callosum, MID: mid-posterior. Significant correlations surviving FDR 
correction are in bold.  
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Graphical abstract 
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Highlights 
 Cerebral and cerebellar atrophy developed in 9 patients with LGI1 encephalitis. 
 Modified Rankin score at onset correlated with volumes of the cerebellar grey matter. 
 Addenbrooke’s Cognitive Examination at follow-up correlated with putaminal volume. 
 Fractional anisotropy and mean diffusivity showed wide-spread white matter changes. 
 MR-spectroscopy showed reduced glutamine/glutamate concentration in the white matter. 
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